BMY Bristol-Myers Squibb

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Company profile

Giovanni Caforio
Fiscal year end
IRS number

BMY stock data


Press releases

Pro users get this 30m faster
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma....
16 Apr 21
Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and Drug Administration
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
14 Apr 21
Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates
Pyramid Biosciences Announces Leadership Team Expansion
14 Apr 21
Brian Lestini, MD, PhD, named Chief Medical Officer Jeffrey Wasserman, JD, named General Counsel Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly
Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
13 Apr 21
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
10 Apr 21


10 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 14.97B 14.97B 14.97B 14.97B 14.97B 14.97B
Cash burn (monthly) 1.63B (positive/no burn) 3.48B 572.58M (positive/no burn) (positive/no burn)
Cash used (since last report) 5.87B n/a 12.56B 2.06B n/a n/a
Cash remaining 9.1B n/a 2.41B 12.91B n/a n/a
Runway (months of cash) 5.6 n/a 0.7 22.5 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Apr 21 Elizabeth Mily Common Stock, $0.10 par value Payment of exercise Dispose F No No 62.93 1,139 71.68K 4,241
1 Apr 21 Elizabeth Mily Common Stock, $0.10 par value Option exercise Aquire M No No 0 2,684 0 5,380
1 Apr 21 Elizabeth Mily Common Stock, $0.10 par value Payment of exercise Dispose F No No 62.93 1,813 114.09K 2,696
1 Apr 21 Elizabeth Mily Common Stock, $0.10 par value Other Aquire J No No 0 847 0 4,509
1 Apr 21 Elizabeth Mily Common Stock, $0.10 par value Option exercise Aquire M No No 0 3,662 0 3,662
1 Apr 21 Elizabeth Mily RSU Common Stock, $0.10 par value Option exercise Dispose M No No 0 2,684 0 8,054
1 Apr 21 Elizabeth Mily Market Share Units Common Stock, $0.10 par value Option exercise Dispose M No No 0 3,662 0 10,987
31 Mar 21 Yale Phyllis R Deferred Share Units Common Stock, $0.10 par value Grant Aquire A No No 63.13 455.409 28.75K 9,465.193
31 Mar 21 Storch Gerald L Deferred Share Units Common Stock, $0.10 par value Grant Aquire A No No 63.13 554.412 35K 63,711.197
31 Mar 21 Samuels Theodore R. II Deferred Share Units Common Stock, $0.10 par value Grant Aquire A No No 63.13 514.811 32.5K 25,159.627

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

74.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2293 2160 +6.2%
Opened positions 276 138 +100.0%
Closed positions 143 114 +25.4%
Increased positions 918 864 +6.3%
Reduced positions 846 887 -4.6%
13F shares
Current Prev Q Change
Total value 102.66B 99.55B +3.1%
Total shares 1.65B 1.64B +1.1%
Total puts 20.66M 20.68M -0.1%
Total calls 24.15M 19.03M +26.9%
Total put/call ratio 0.9 1.1 -21.3%
Largest owners
Shares Value Change
Vanguard 199.34M $12.37B -0.4%
BLK Blackrock 172.46M $10.7B +6.2%
STT State Street 94.16M $5.89B -3.4%
JPM JPMorgan Chase & Co. 72.35M $4.49B +9.0%
FMR 59.26M $3.68B -5.4%
Wellington Management 45.74M $2.84B -15.3%
Geode Capital Management 34.03M $2.11B +0.9%
BRK.A Berkshire Hathaway 33.34M $2.07B +11.2%
BAC Bank Of America 32.31M $2B -1.7%
AMP Ameriprise Financial 28.75M $1.78B -2.2%
Largest transactions
Shares Bought/sold Change
Norges Bank 24.47M +24.47M NEW
Renaissance Technologies 18.48M -12.1M -39.6%
BLK Blackrock 172.46M +10.05M +6.2%
Wellington Management 45.74M -8.24M -15.3%
Citadel Advisors 110.12K -7M -98.5%
JPM JPMorgan Chase & Co. 72.35M +5.99M +9.0%
BEN Franklin Resources 14.3M +5.06M +54.8%
Two Sigma Advisers 1.29M -3.94M -75.3%
HBCYF HSBC 6.9M +3.88M +128.6%
MS Morgan Stanley 25.02M +3.86M +18.2%
Content analysis
H.S. freshman Avg
New words: absence, accredited, ADC, adenocarcinoma, ADR, affirmed, aforementioned, aim, alcoholic, AML, anaplastic, Ann, Anokion, antidilutive, aprpoved, Ascend, atezolizumab, atrioventricular, banc, BCBSA, BCBSM, begun, bereavement, Black, Blue, bolstered, Boudry, Bravo, Breyanzi, Bristol, broader, BSC, carboplatin, cardiomyopathy, career, carefully, causation, certified, chemoradiation, chemoradiotherapy, child, Cigna, cisplatin, clause, clear, CMMoL, College, Color, commitee, commuter, compel, conspiracy, Cooperation, copay, corticosteroid, count, creation, cultivating, curative, cytarabine, cytokine, DAYBREAK, dental, deplete, derica, deucravacitinib, discourage, discouraging, discretionary, distancing, DMC, doctrine, doubling, downturn, Dragonfly, drawn, dynamic, dynamically, economy, elder, Elizabeth, embody, empower, en, endoscopic, enlarged, epidermal, equated, exacerbate, exciting, expenditure, family, feasibility, feedback, filtration, forum, fullest, gastroesophageal, gender, Genitourinary, glomerular, HCSC, heard, HHS, home, HPI, hypertrophic, hypomethylating, iberdomide, ICE, idecabtagene, IDHENTIFY, immunodeficiency, inapplicable, incentivize, induction, ineligible, influx, inspire, instance, intervention, isocitrate, JAK, junction, Kaposi, KarMMa, knowledge, lab, Latino, leader, learn, learning, led, legislature, lentiviral, lessen, lessor, lever, Living, lt, Lupin, lymphoblastic, Malignant, mavacamten, metastic, methyltransferase, MGMT, MHLW, military, Mily, Minnesota, mirror, mosaic, multiforme, myelomonocytic, MyoKardia, Negro, neoplasm, NMPA, noninfringement, nurturing, obstructive, onset, onsite, Ontario, Onureg, opted, Organisation, organizational, ORR, outpatient, Overnight, Pan, pandemic, parent, parental, parity, PASI, paula, pausing, PBRG, pemetrexed, pet, pharmacy, phishing, pioneering, Pleural, POETYK, Powell, precision, prejudgment, preliminarily, pretreated, PRIDE, prolonged, Prospanica, published, pulmonary, Quebec, recharge, recommenced, reconsider, recovered, recruiting, relieve, remission, remote, renegotiate, renegotiated, representation, residual, restarted, resumed, resumption, retiree, reverted, reward, rice, RMS, RNA, ruxolitinib, sarcoma, scarcity, Schwab, score, Septal, shape, shelter, Shield, sick, signature, Singapore, slowdown, sNDA, SOFR, solvency, soul, sPGA, spleen, splenomegaly, static, statue, steering, stimulating, stretch, stringent, strive, subgroup, sudden, surrogate, survey, switch, switching, Symposium, tangible, Tecentriq, tenure, thereunder, thriving, thrombocythaemia, Tolerance, training, transient, translocation, travel, traveling, TriPhase, True, tuition, Twelfth, UC, UHS, unblinded, undertook, unemployment, unified, unsatisfactory, unused, unyielding, USD, vacancy, vacation, vaccine, validly, valuable, vector, venue, vicleucel, vision, volunteer, warehousing, wider, withdrew, workday, workplace, worse, writing, xii, xiii, xiv, Zeposia, zone
Removed: acceptance, accessing, adnectin, age, agonist, analgesic, ASEAN, asymptomatic, autoimmunity, bad, Belgium, bleeding, build, buyer, cabiralizumab, Cardioxyl, Connecticut, constitute, continuously, CytomX, depreciated, dMMR, dual, Duchenne, Dystrophy, Elicker, enactment, expecting, expressly, false, favor, financed, fragment, graduate, Gulf, IFM, India, infused, innate, intermediate, Investor, iPierian, John, lymph, minimally, minimize, modulate, Muscular, nominated, Palsy, passed, Perfalgan, postgraduate, powder, Prime, Probody, profession, prospectively, rated, realign, Redwood, revoked, Secretary, Silver, simplify, step, STING, stroke, subcutaneously, substitution, summarize, Supranuclear, symptomatic, transitional, undergone, uniquely, ViiV, vitamin, VTE, Wallingford